Klinik für Strahlentherapie und Radioonkologie

[["dc.bibliographiccitation.firstpage","1141"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Neuroradiology"],["dc.bibliographiccitation.lastpage","1148"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Schmitt, Niclas"],["dc.contributor.author","Floca, Ralf O."],["dc.contributor.author","Paech, Daniel"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Neuberger, Ulf"],["dc.contributor.author","Bendszus, Martin"],["dc.contributor.author","Möhlenbruch, Markus A."],["dc.contributor.author","Vollherbst, Dominik F."],["dc.date.accessioned","2022-11-17T10:17:48Z"],["dc.date.available","2022-11-17T10:17:48Z"],["dc.date.issued","2021-12"],["dc.description.abstract","A major drawback of liquid embolic agents (LEAs) is the generation of imaging artifacts (IA), which may represent a crucial obstacle for the detection of periprocedural hemorrhage or subsequent radiosurgery of cerebral arteriovenous malformations (AVMs). This study aimed to compare the IAs of Onyx, Squid and PHIL in a novel three-dimensional in vitro AVM model in conventional computed tomography (CT) and cone-beam CT (CBCT)."],["dc.identifier.doi","10.1007/s00062-021-01013-5"],["dc.identifier.pmid","33852036"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117096"],["dc.language.iso","en"],["dc.relation.eissn","1869-1447"],["dc.relation.issn","1869-1439"],["dc.title","Imaging Artifacts of Nonadhesive Liquid Embolic Agents in Conventional and Cone-beam CT in a Novel in Vitro AVM Model"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","255"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Pulmonary Medicine"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Blasi, Miriam"],["dc.contributor.author","Eichhorn, Martin E."],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Winter, Hauke"],["dc.contributor.author","Heußel, Claus Peter"],["dc.contributor.author","Herth, Felix J."],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Kriegsmann, Katharina"],["dc.contributor.author","Kriegsmann, Mark"],["dc.contributor.author","Stenzinger, Albrecht"],["dc.contributor.author","Bischoff, Helge"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Kuon, Jonas"],["dc.date.accessioned","2022-11-17T10:41:42Z"],["dc.date.available","2022-11-17T10:41:42Z"],["dc.date.issued","2022-06-28"],["dc.description.abstract","Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population."],["dc.identifier.doi","10.1186/s12890-022-02043-6"],["dc.identifier.pmid","35761214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117104"],["dc.language.iso","en"],["dc.relation.issn","1471-2466"],["dc.title","Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","253"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neurosurgery"],["dc.bibliographiccitation.lastpage","260"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Paul, Angela"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Welzel, Thomas"],["dc.contributor.author","Sprave, Tanja"],["dc.contributor.author","Hommertgen, Adriane"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Klüter, Sebastian"],["dc.contributor.author","Schubert, Kai"],["dc.contributor.author","Klose, Christina"],["dc.contributor.author","Kieser, Meinhard"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T09:11:12Z"],["dc.date.available","2020-07-16T09:11:12Z"],["dc.date.issued","2019"],["dc.description.abstract","Stereotactic radiosurgery (SRS) of brain metastases (BM) is recommended in oligometastatic scenarios as a less toxic treatment alternative to whole-brain radiotherapy. Recent findings support SRS for patients with multiple (>3) BM. Furthermore, advances in MR imaging have facilitated the detection of very small BM, as advances in SRS technology have facilitated the highly conformal and simultaneous treatment of multiple target lesions."],["dc.identifier.doi","10.1093/neuros/nyy026"],["dc.identifier.pmid","29554321"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67096"],["dc.language.iso","en"],["dc.relation.eissn","1524-4040"],["dc.relation.issn","0148-396X"],["dc.title","Robotic Radiosurgery for Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence (CYBER-SPACE)-A Single-Center Prospective Randomized Trial"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","641"],["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Böhm, Karina"],["dc.contributor.author","Weber, Dorothea"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Schlaich, Fabian"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Paul, Angela"],["dc.contributor.author","Haefner, Matthias F."],["dc.contributor.author","Katayama, Sonja"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Hoegen, Philipp"],["dc.contributor.author","Löw, Sarah"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Bernhardt, Denise"],["dc.date.accessioned","2020-07-16T10:33:04Z"],["dc.date.available","2020-07-16T10:33:04Z"],["dc.date.issued","2018"],["dc.description.abstract","Introduction: The purpose of this article is to report our institution's 10-year experience on palliative radiotherapy for the treatment of leptomeningeal carcinomatosis (LC), assessing survival, neurologic outcome, and prognostic factors. Patients and methods: We retrospectively analyzed 110 patients who received palliative radiotherapy for LC between 2008 and 2018. The most common histologies were breast cancer (n = 43, 39.1%) and non-small cell lung cancer (NSCLC) (n = 31, 28.2%). Radiotherapy was administered as whole-brain radiotherapy (WBRT) (n = 51, 46.4%), focal spinal RT (n = 11, 10.0%) or both (n = 47, 42.7%). Twenty-five patients (22.7%) were selected for craniospinal irradiation. Clinical performance and neurologic function were quantified on the neurologic function scale (NFS) before and in response to therapy. A Cox Proportional Hazards model with univariate and multivariate analysis was fitted for survival. Results: Ninety-eight patients (89.1%) died and 12 (10.9%) were alive at the time of analysis. Median OS from LC diagnosis and from the beginning of RT was 13.9 weeks (IQR: 7.1-34.0) and 9.9 weeks (IQR: 5.3-26.3), respectively. In univariate analysis, prognostic of longer OS were a Karnofsky performance scale index (KPI) of ≥70% (HR 0.20, 95%-CI: [0.13; 0.32], p < 0.001), initially moderate neurological deficits (NFS ≤2) (HR 0.32, 95% CI: [0.19; 0.52], p < 0.001), symptom response to RT (HR 0.41, 95%-CI: [0.26; 0.67], p < 0.001) and the administration of systemic therapy (HR 0.51, 95%-CI: [0.33; 0.78], p = 0.002). Prognostic of inferior OS were high-grade myelosuppression (HR 1.78, 95% CI: [1.06; 3.00], p = 0.03) and serum LDH levels >500 U/l (HR 3.62, 95% CI: [1.76; 7.44], p < 0.001). Clinical performance, symptom response and serum LDH stayed independently prognostic for survival in multivariate analysis. RT was well-tolerated and except for grade III myelosuppression in 19 cases (17.3%), no high-grade acute toxicities were observed. Neurologic symptom stabilization was achieved in 83 cases (75.5%) and a sizeable improvement in 39 cases (35.5%). Conclusion: Radiotherapy is a well-tolerated and efficacious means of providing symptom palliation for patients with LC, delaying neurologic deterioration while probably not directly influencing survival. Prognostic factors such as clinical performance, neurologic response and serum LDH can be used for patient stratification to facilitate treatment decisions."],["dc.identifier.doi","10.3389/fonc.2018.00641"],["dc.identifier.pmid","30671384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67172"],["dc.language.iso","en"],["dc.relation.issn","2234-943X"],["dc.title","Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiation Oncology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Sprave, Tanja"],["dc.contributor.author","Hees, Katharina"],["dc.contributor.author","Bruckner, Thomas"],["dc.contributor.author","Foerster, Robert"],["dc.contributor.author","Bostel, Tilman"],["dc.contributor.author","Schlampp, Ingmar"],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Nicolay, Nils Henrik"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Rief, Harald"],["dc.date.accessioned","2022-11-17T10:41:38Z"],["dc.date.available","2022-11-17T10:41:38Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1186/s13014-018-1082-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117106"],["dc.relation.issn","1748-717X"],["dc.title","The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","105"],["dc.bibliographiccitation.journal","Lung Cancer"],["dc.bibliographiccitation.lastpage","112"],["dc.bibliographiccitation.volume","148"],["dc.contributor.author","Christopoulos, P."],["dc.contributor.author","Kirchner, M."],["dc.contributor.author","Roeper, J."],["dc.contributor.author","Saalfeld, F."],["dc.contributor.author","Janning, M."],["dc.contributor.author","Bozorgmehr, F."],["dc.contributor.author","Magios, N."],["dc.contributor.author","Kazdal, D."],["dc.contributor.author","Volckmar, A. L."],["dc.contributor.author","Brückner, L. M."],["dc.contributor.author","Bochtler, T."],["dc.contributor.author","Kriegsmann, M."],["dc.contributor.author","Endris, V."],["dc.contributor.author","Penzel, R."],["dc.contributor.author","Kriegsmann, K."],["dc.contributor.author","Eichhorn, M."],["dc.contributor.author","Herth, F. J. F."],["dc.contributor.author","Heussel, C. P."],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Schneider, M. A."],["dc.contributor.author","Muley, T."],["dc.contributor.author","Meister, M."],["dc.contributor.author","Faehling, M."],["dc.contributor.author","Fischer, J. R."],["dc.contributor.author","Heukamp, L."],["dc.contributor.author","Schirmacher, P."],["dc.contributor.author","Bischoff, H."],["dc.contributor.author","Wermke, M."],["dc.contributor.author","Loges, S."],["dc.contributor.author","Griesinger, F."],["dc.contributor.author","Stenzinger, A."],["dc.contributor.author","Thomas, M."],["dc.date.accessioned","2022-11-17T10:41:09Z"],["dc.date.available","2022-11-17T10:41:09Z"],["dc.date.issued","2020"],["dc.description.abstract","Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters."],["dc.identifier.doi","10.1016/j.lungcan.2020.08.007"],["dc.identifier.pmid","32871455"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117100"],["dc.language.iso","en"],["dc.relation.eissn","1872-8332"],["dc.relation.issn","0169-5002"],["dc.title","Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","760024"],["dc.bibliographiccitation.journal","Frontiers in Psychology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Sauer, Christina"],["dc.contributor.author","Lambert, Lena"],["dc.contributor.author","Regnery, Sebastian"],["dc.contributor.author","Windisch, Paul"],["dc.contributor.author","Zaoui, Karim"],["dc.contributor.author","Freudlsperger, Christian"],["dc.contributor.author","Moratin, Julius"],["dc.contributor.author","Farnia, Benjamin"],["dc.contributor.author","Nikendei, Christoph"],["dc.contributor.author","Krauss, Juergen"],["dc.contributor.author","Ehrenthal, Johannes C."],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Friederich, Hans-Christoph"],["dc.contributor.author","Maatouk, Imad"],["dc.date.accessioned","2022-11-17T11:12:55Z"],["dc.date.available","2022-11-17T11:12:55Z"],["dc.date.issued","2021"],["dc.description.abstract","This single-center, single-arm trial investigates the feasibility of a psycho-oncological care program, which aims to reduce psychological distress and improve compliance with radiotherapy with mask fixation in patients with head and neck cancer or brain malignancies. The care program comprised (1) a screening/needs assessment and (2) the provision of a psycho-oncological intervention using imaginative stabilization techniques for distressed patients (distress due to anxiety ≥5) or in a case of subjective interest in the psycho-oncological intervention. Another allocation path to the intervention was directly through the radiation oncologist in charge who classified the patient as: in need of support to tolerate the immobilization device. Of a total of 1,020 screened patients, 257 (25.2%) patients indicated a distress ≥5 and 141 (13.8%) patients reported panic attacks. 25% of the patients reported a subjective interest in psycho-oncological support. A total of 35 patients received the psycho-oncological intervention, of which 74% were assigned by radiation oncologists. In this small patient cohort, no significant pre-post effects in terms of depression, anxiety, distress, and quality of life (mental and physical component scores) could be detected. Our results indicate a good feasibility (interdisciplinary workflow and cooperation, allocation by physicians in charge) of the psycho-oncological care program for this cohort of patients before radiotherapy with mask fixation. The screening results underline the high psychological distress and demand for psycho-oncological support. However, since the utilization of our intervention was low, future studies should reduce the barriers and improve compliance to psycho-oncological services by these patients.Clinical Trial Registration: https://www.drks.de/drks_web/setLocale_EN.do #DRKS00013493."],["dc.identifier.doi","10.3389/fpsyg.2021.760024"],["dc.identifier.pmid","34975651"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117119"],["dc.language.iso","en"],["dc.relation.issn","1664-1078"],["dc.title","Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Bougatf, Nina"],["dc.contributor.author","Klüter, Sebastian"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Debus, J."],["dc.contributor.author","Paul, A."],["dc.date.accessioned","2020-07-10T07:20:48Z"],["dc.date.available","2020-07-10T07:20:48Z"],["dc.date.issued","2017"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66975"],["dc.title","Robotic radiosurgery using „Cyberknife M6“ at Heidelberg University Hospital – initial clinical experience in the first 145 patients"],["dc.type","report"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1309"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Der Urologe. Ausgabe A"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Rieken, S."],["dc.contributor.author","El Shafie, Rami"],["dc.date.accessioned","2020-07-10T08:21:05Z"],["dc.date.available","2020-07-10T08:21:05Z"],["dc.date.issued","2018-11"],["dc.description.abstract","Photon radiotherapy has repeatedly been described to elicit effects beyond mere inhibition of tumor cell clonogenicity: immunomodulatory phenomena including radiation-induced expression of tumor-associated antigens, increased recruitment and functioning of immunocompetent cells and secretion of immunomodulatory messengers have been described to explain the radiation responses of tumor lesions outside of irradiated volumes (\"abscopal effect\") in both preclinical models and clinical cases. With radiotherapy only, the abscopal effect is only rarely observed, but several trials have suggested combining modern immunotherapy with radiation to increase both frequency and intensity of the abscopal effect. Urological malignancies are commonly described as immunogenic malignancies. Both radiotherapy and immunotherapy are typical components of modern treatment regimes. Combining both modalities is expected to result in increased efficacy within and beyond irradiated lesions. However, prospective clinical trials have not yet provided mature results for oncological efficacy and toxicity of combined modality treatments in urological malignancies. This review details the preclinical rationale for combining photon radiotherapy with immunotherapy, summarizes early clinical experience, and provides a perspective for potential, future innovative combination treatments."],["dc.description.abstract","Die Bestrahlung mit Photonen ruft jenseits ihres zytotoxischen Effekts auf die Klonogenität von Tumorzellen Immunmodulationen hervor, die mit der vermehrten Expression tumorassoziierter Antigene, der erhöhten Rekrutierung und Funktionalität immunkompetenter Zellen sowie dem Freiwerden immunmodulierender Botenstoffe einhergehen. Präklinisch und vereinzelt auch klinisch ist gezeigt worden, dass diese Phänomene zur Strahlenwirkung auch jenseits des bestrahlten Volumens führen können („abscopal effect“). Bei alleiniger Strahlentherapie ist dieser Effekt nur selten zu beobachten, während mehrere Studien nahelegen, dass die kombinierte Gabe einer immunonkologischen Therapie zur Bestrahlung den „abscopal effect“ in seiner Häufigkeit und Intensität steigern kann. Urologische Tumorerkrankungen werden typischerweise zu den immunogenen Tumorentitäten gezählt, und sowohl die Radiotherapie als auch die Immuntherapie gehören aktuell zu den fest etablierten Therapiemodalitäten. Von der Kombination beider Verfahren ist eine gesteigerte Effektivität innerhalb wie außerhalb der Strahlenvolumina zu erwarten und bis dato in kleineren Studien gezeigt worden. Nun ist es größeren, aktuell rekrutierenden Studien vorbehalten, die klinische Effektivität und die Toxizität verschiedenartig kombinierter Therapieregime zu untersuchen. Die vorliegende Arbeit erläutert die präklinische Rationale der Radioimmuntherapie, fasst aktuelle klinische Erfahrungen zusammen und erlaubt einen Ausblick in potentielle, zukünftige und innovative Kombinationstherapien."],["dc.identifier.doi","10.1007/s00120-018-0789-x"],["dc.identifier.pmid","30324394"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66995"],["dc.language.iso","other"],["dc.relation.eissn","1433-0563"],["dc.relation.issn","0340-2592"],["dc.title","Kombinationen von Strahlen- und Immuntherapie für urologische Tumorerkrankungen"],["dc.title.alternative","Combining radiotherapy with immunotherapy for urological malignancies"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1916"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Küchler, Maike; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Adeberg, Sebastian; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Herfarth, Klaus; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","König, Laila; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Lang, Kristin; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Hörner-Rieber, Juliane; 4Heidelberg Institute of Radiation Oncology (HIRO), INF 400, 69120 Heidelberg, Germany; juliane.hoerner-rieber@med.uni-heidelberg.de"],["dc.contributor.affiliation","Plinkert, Peter Karl; 9Department of Otolaryngology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; peter.plinkert@med.uni-heidelberg.de"],["dc.contributor.affiliation","Wick, Wolfgang; 8Department of Neurology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; wolfgang.wick@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sahm, Felix; 3Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Heidelberg, INF 280, 69120 Heidelberg, Germany; felix.sahm@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sprengel, Simon David; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Debus, Jürgen; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Bernhardt, Denise; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.author","Küchler, Maike"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Plinkert, Peter Karl"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Sahm, Felix"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Sprengel, Simon David"],["dc.contributor.author","Debus, Jürgen"],["dc.date.accessioned","2022-05-02T08:09:33Z"],["dc.date.available","2022-05-02T08:09:33Z"],["dc.date.issued","2022"],["dc.date.updated","2022-05-05T11:24:31Z"],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.identifier.doi","10.3390/cancers14081916"],["dc.identifier.pii","cancers14081916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","2072-6694"],["dc.title","Outcome after Radiotherapy for Vestibular Schwannomas (VS)—Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]